“消臌贴膏”联合肝病治疗仪治疗肝硬化门脉高压疗效观察
|
摘要
目的:观察"消臌贴膏"在肝区外敷联合肝病治疗仪照射治疗肝硬化门脉高压的的临床疗效。方法:60例肝硬化住院患者完全随机分为治疗组、对照组,每组患者各30例。治疗组是在西医常规治疗基础上给予"消臌贴膏"肝区外敷联合DSG-Ⅰ型肝病治疗仪治疗;对照组是在西医常规对症支持治疗基础上单独使用DSG-Ⅰ型肝病治疗仪治疗。治疗前后运用彩色多普勒观察门脉血流动力学的变化,并观察患者的主要症状量化积分变化和临床总疗效情况,以1个月为1个疗程。结果:两组经治疗后,治疗组门静脉主干内径、血流速度及门脉血流量改善程度优于对照组(P<0.01或P<0.05);治疗组在改善胁痛、腹胀、倦怠乏力、小便发黄、身目发黄症状方面有统计学意义(P<0.01或P<0.05),但食欲、睡眠症状无统计学意义(P>0.05);治疗组总有效率93.3%,对照组70%,治疗组优于对照组(P<0.05)。结论:"消臌贴膏"联合肝病治疗仪治疗肝硬化门脉高压,比单纯运用肝病治疗仪更能有效地减轻肝硬化患者的临床症状,降低门脉高压、促进门静脉血液循环,且简易价廉,无不良反应。
Objective: To observe the clinical efficacy of improving clinical symptoms of liver cirrhosis treated by Xiaogu Plaster combined with medical instrument on hepatic diseases. Methods: All 60 liver cirrhosis inpatients which were randomly divided into two groups: treatment group and control group and each group had 30 cases. Treatment group on the basis of usual supportive Western medicine treatment,used Xiaogu Plaster combined with medical instrument on hepatic diseases. Control group on the basis of usual supportive Western medicine treatment,used medical instrument on hepatic diseases. The hemodynamic changes in portal veins were observed by color Doppler ultrasonograph and the total clinical curative effect and TCM symptoms quantitative integral were observed for a month,too. Results: Compared with control group,the improving of portal venous diameter,flow velocity of blood and its blood flow had very significant differences after treatment in treatment group( P<0.01 or P<0.05). Improving pain of liver area,abdominal distension,languid,urine,skin and sclera yellowing in treatment group had significant differences( P< 0.01 or P< 0.05),but there were no significant differences of appetite and sleep symptoms( P>0.05). Treatment group's total effective rate was 93.3% and control group's 70%. It had statistical significance comparing the two groups( P < 0. 05). Conclusion: Using Xiaogu Plaster combined with medical instrument on hepatic diseases to treat liver cirrhosis can effectively improve the clinical symptoms and better reduce the portal hypertension and promote the blood circulation of portal vein,which are better than simply using medical instrument on hepatic diseases. It provides a simple,cheap,safe and effective external treatment of TCM to the clinical treatment of liver cirrhosis.
Objective: To observe the clinical efficacy of improving clinical symptoms of liver cirrhosis treated by Xiaogu Plaster combined with medical instrument on hepatic diseases. Methods: All 60 liver cirrhosis inpatients which were randomly divided into two groups: treatment group and control group and each group had 30 cases. Treatment group on the basis of usual supportive Western medicine treatment,used Xiaogu Plaster combined with medical instrument on hepatic diseases. Control group on the basis of usual supportive Western medicine treatment,used medical instrument on hepatic diseases. The hemodynamic changes in portal veins were observed by color Doppler ultrasonograph and the total clinical curative effect and TCM symptoms quantitative integral were observed for a month,too. Results: Compared with control group,the improving of portal venous diameter,flow velocity of blood and its blood flow had very significant differences after treatment in treatment group( P<0.01 or P<0.05). Improving pain of liver area,abdominal distension,languid,urine,skin and sclera yellowing in treatment group had significant differences( P< 0.01 or P< 0.05),but there were no significant differences of appetite and sleep symptoms( P>0.05). Treatment group's total effective rate was 93.3% and control group's 70%. It had statistical significance comparing the two groups( P < 0. 05). Conclusion: Using Xiaogu Plaster combined with medical instrument on hepatic diseases to treat liver cirrhosis can effectively improve the clinical symptoms and better reduce the portal hypertension and promote the blood circulation of portal vein,which are better than simply using medical instrument on hepatic diseases. It provides a simple,cheap,safe and effective external treatment of TCM to the clinical treatment of liver cirrhosis.
引文
[1]中华医学会传染病与寄生虫病分会,肝病学分会.病毒性肝炎防治方案[S].中华肝脏病杂志,2000,8(6):324-329.
[2]中华医学会肝病学分会,感染病学分会.慢性乙型肝炎防治指南(2010年版)[S].实用肝脏病杂志,2011,14(2):81-89.
[3]危北海,张万岱,陈治水,等.肝硬化中西医结合诊疗方案[J].世界华人消化杂志,2004,12(11):2694-2696.
[4]中国中西医结合学会消化疾病专业委员会.肝硬化腹水的中西医结合诊疗共识意见[S].中国中西医结合杂志,2011,31(9):1171-1174.
[5]姜慧卿,张晓岚,靳洪涛,等.肝硬化门静脉系统血流动力学改变的彩色多普勒超声研究[J].中国医学影像学杂志,2001,9(5):381-382.
[6]中国中西医结合学会消化系统疾病专业委员会.肝硬化中西医结合诊疗共识[S].中国中西医结合消化杂志,2011,19(4):277-279.
[7]郑筱萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:240-241.
[8]盛旧光.朱清静,徐建良,等.肝炎肝硬化失代偿期患者中医证型临床特点分析[J].中西医结合肝病杂志,2007,17(1):38-40.
[9]池晓玲,萧焕明.肝炎后肝纤维化中医治疗近况[J].现代消化及介入诊疗,2005,10(增刊):92-93.
[10]施维群,茹清静,蔡国英,等.中药脐透消臌贴膏敷脐治疗肝硬化门静脉高压疗效观察[J].中国中西医结合杂志,2008,28(7):642-645.
[11]施维群,倪伟.中药脐部贴敷对肝硬化内毒血症的影响[J].中华中医药杂志,2010,25(3):452-455.
[12]陈素美,徐江雁.中药莱菔子药理及临床应用研究回顾[J].时珍国医国药,2007,18(12):3117-3118.
[13]CAI Xiao-Hui,WANG Shuai,CHEN Bao-An.Research Advances on the Pharmacological Effects of Tetrandrine[J].Chinese Journal of Natural Medicines,2011,9(6):473-480.
[14]杨明.高速逆流色谱分离地龙中抗血栓活性成分的研究[J].中国医药导刊,2010,12(7):32-35.
[15]易文龙,陈建明.水蛭、桃仁、黄芪、当归合剂对小鼠血吸虫性肝纤维化的影响[J].中国血吸虫病防治杂志,2004,16(1):32-34.
[16]胡玉兰,张忠义,林敬明.中药砂仁的化学成分和药理活性研究进展[J].中药材,2005,28(1):72-74.
[17]吴晓松,肖飞,张志东,等.砂仁挥发油中乙酸龙脑酯的镇痛作用及其机制研究[J].中药材,2005,28(6):505-506.
[18]严娅娟,曹曼,张丹雁,等.砂仁现代药理的国内外研究[J].化工与制药,2013,176(7):52-53.
[19]李娌,王学美.淫羊藿苷药理作用研究进展[J].中国中药杂志,2008,33(23):2727-2731.
[20]王小东,付晓琳,路立业,等.HD肝病治疗仪在肝硬化患者中的应用效果观察[J].海南医学,2012,23(9):31-33.
[21]Frank S,Oliver L,Lebreton-De Coster C,et al.Infrared radiation affects the mitochondrial pathway of apoptosis in human fibroblasts[J].J Invest Dermatol,2004,123(5):823-831.
[22]Kao MJ,Sheen LY.Effects of infrared and low-power laster irradiation on cell viability,glutathione-related enzyme activities in primary rat hepatocytes[J].J Formos Med Assoc,2003,102(7):486-491.
[23]赵长青,薛惠明,顾宏图,等.电脑生物信息肝病治疗仪对正常人肝血流的影响[J].中西医结合肝病杂志,2004,14(5):290-291.
[2]中华医学会肝病学分会,感染病学分会.慢性乙型肝炎防治指南(2010年版)[S].实用肝脏病杂志,2011,14(2):81-89.
[3]危北海,张万岱,陈治水,等.肝硬化中西医结合诊疗方案[J].世界华人消化杂志,2004,12(11):2694-2696.
[4]中国中西医结合学会消化疾病专业委员会.肝硬化腹水的中西医结合诊疗共识意见[S].中国中西医结合杂志,2011,31(9):1171-1174.
[5]姜慧卿,张晓岚,靳洪涛,等.肝硬化门静脉系统血流动力学改变的彩色多普勒超声研究[J].中国医学影像学杂志,2001,9(5):381-382.
[6]中国中西医结合学会消化系统疾病专业委员会.肝硬化中西医结合诊疗共识[S].中国中西医结合消化杂志,2011,19(4):277-279.
[7]郑筱萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:240-241.
[8]盛旧光.朱清静,徐建良,等.肝炎肝硬化失代偿期患者中医证型临床特点分析[J].中西医结合肝病杂志,2007,17(1):38-40.
[9]池晓玲,萧焕明.肝炎后肝纤维化中医治疗近况[J].现代消化及介入诊疗,2005,10(增刊):92-93.
[10]施维群,茹清静,蔡国英,等.中药脐透消臌贴膏敷脐治疗肝硬化门静脉高压疗效观察[J].中国中西医结合杂志,2008,28(7):642-645.
[11]施维群,倪伟.中药脐部贴敷对肝硬化内毒血症的影响[J].中华中医药杂志,2010,25(3):452-455.
[12]陈素美,徐江雁.中药莱菔子药理及临床应用研究回顾[J].时珍国医国药,2007,18(12):3117-3118.
[13]CAI Xiao-Hui,WANG Shuai,CHEN Bao-An.Research Advances on the Pharmacological Effects of Tetrandrine[J].Chinese Journal of Natural Medicines,2011,9(6):473-480.
[14]杨明.高速逆流色谱分离地龙中抗血栓活性成分的研究[J].中国医药导刊,2010,12(7):32-35.
[15]易文龙,陈建明.水蛭、桃仁、黄芪、当归合剂对小鼠血吸虫性肝纤维化的影响[J].中国血吸虫病防治杂志,2004,16(1):32-34.
[16]胡玉兰,张忠义,林敬明.中药砂仁的化学成分和药理活性研究进展[J].中药材,2005,28(1):72-74.
[17]吴晓松,肖飞,张志东,等.砂仁挥发油中乙酸龙脑酯的镇痛作用及其机制研究[J].中药材,2005,28(6):505-506.
[18]严娅娟,曹曼,张丹雁,等.砂仁现代药理的国内外研究[J].化工与制药,2013,176(7):52-53.
[19]李娌,王学美.淫羊藿苷药理作用研究进展[J].中国中药杂志,2008,33(23):2727-2731.
[20]王小东,付晓琳,路立业,等.HD肝病治疗仪在肝硬化患者中的应用效果观察[J].海南医学,2012,23(9):31-33.
[21]Frank S,Oliver L,Lebreton-De Coster C,et al.Infrared radiation affects the mitochondrial pathway of apoptosis in human fibroblasts[J].J Invest Dermatol,2004,123(5):823-831.
[22]Kao MJ,Sheen LY.Effects of infrared and low-power laster irradiation on cell viability,glutathione-related enzyme activities in primary rat hepatocytes[J].J Formos Med Assoc,2003,102(7):486-491.
[23]赵长青,薛惠明,顾宏图,等.电脑生物信息肝病治疗仪对正常人肝血流的影响[J].中西医结合肝病杂志,2004,14(5):290-291.